Angle Plc Stock Price, News & Analysis

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced new share option grants under its Long-Term Incentive Plan (LTIP) and staff share option plans. The company approved 12 million LTIP Options for executive directors and up to 13.8 million Staff Share Options.

The allocation considers that no bonuses were awarded for three consecutive years to conserve cash. The Staff Share Options are priced at 10.00 pence per share, 2.6% above the closing price of 9.75 pence on March 20, 2025. Following these grants, ANGLE will have outstanding options over 51,369,480 Ordinary Shares, representing 13.7% of issued capital, within the approved 16% limit.

The LTIP Options include a three-year performance period plus a two-year holding period, with performance conditions linked to share price CAGR above the June 2024 funding round price of 15.00 pence per share.

ANGLE plc (ANPCY) has announced successful completion of key development projects with AstraZeneca and Eisai. The company has developed two assays for AstraZeneca: a prostate cancer androgen receptor (AR) assay and a multi-cancer DDR micronuclei assay for DNA damage detection in CTCs.

The AR therapeutic market is projected to reach $9.2 billion by 2033, with over 46,000 patients in 181 clinical studies. The DDR therapeutic market, valued at $8.2 billion in 2024, is expected to grow to $30.3 billion in the next decade.

Additionally, ANGLE's Parsortix-based HER2 assay demonstrated successful results in Eisai's Phase 2 pilot study for breast cancer patients, showing the ability to measure HER2 status changes over time. The HER2 therapeutic market, valued at $9.4 billion in 2023, is projected to reach $13.2 billion by 2030.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced successful results from its dual analysis of circulating tumor DNA (ctDNA) and CTC-DNA using Illumina's technology platform. The study, conducted on 27 lung cancer patients, demonstrated that 100% of untreated patients and 90% of treated patients had cancer mutations identified exclusively in CTC-DNA, not found in ctDNA from the same blood sample.

The research utilized Illumina's customized 79-gene lung cancer panel with NGS completed on the Illumina NextSeq 2000 platform. The dual analysis approach found twice as many mutations compared to single-analyte testing, potentially providing more comprehensive biomarkers for treatment guidance.

Following these positive results, ANGLE has been invited to present their findings at an EACR-Illumina webinar on February 6, 2025. This marks the first joint marketing initiative between ANGLE and Illumina, whose NGS systems are installed across more than 9,500 customers in 155 countries.

ANGLE plc has announced breakthrough research from ETH Zurich published in Nature Medicine, featuring their Parsortix system in a Phase 1 clinical trial for metastatic breast cancer treatment. The study used FDA-approved drug digoxin and demonstrated the Parsortix system's critical role in identifying patients with CTC clusters for targeted treatment.

The trial achieved its primary endpoint, showing significant reduction in CTC cluster size in the treatment group. This proof-of-principle study opens possibilities for developing novel drugs preventing metastasis. Professor Aceto's lab has co-founded PAGE Therapeutics to develop compounds effective at disassociating CTC clusters, with Parsortix expected to play a important role in future development.

The research is particularly significant as metastasis accounts for the majority of cancer-related deaths. The Parsortix system's unique ability to capture CTC clusters makes it valuable for developing drugs targeting metastatic spread, potentially improving patient outcomes across all solid tumors.